Acadia Pharmaceuticals (ACAD) Stock News

RBC Capital lowered its price target for ACADIA Pharmaceuticals from $37.00 to $36.00.

The USPTO issued a Notice of Allowance for a patent covering weight-banded dosing of trofinetide (DAYBUE) for Rett syndrome. The patent is expected to extend U.S. protection from July 2036 to March 2041, including six months of pediatric exclusivity. This strengthens Acadia's IP portfolio for its key Rett syndrome treatment.

Small-cap index edged lower Thursday. ACADIA Pharma down 13% led decliners among Russell 2000 stocks. Biotech names mostly weaker. Gains in GRAIL, Korsana, Securitize, Quantum, and CareDx offset some losses. Major indexes mixed with Nasdaq and S&P 500 flat, Dow off 0.3%.

Acadia Pharmaceuticals Phase 2 remlifanserin narrowly misses primary endpoint, supports Phase 3 continuation

Acadia Pharmaceuticals announced topline results from the phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis. The results are described as phase 3 enabling. No specific efficacy or safety data were provided in the initial release.